Skip to content
Menu

Puma Biotechnology, Inc. PBYI

Full chart Compare
Set alert

Price alert · PBYI

All alert types
7.77 USD 0.00 (+0.00%)

Regular-session close

7.75 -0.02 -0.26%

Pre-market · Nov 16, 7:00 AM ET

Day range unavailable

4.80 52-week range 11.50
YTD
+30.59%
1 year
+56.97%
Market cap
401.70M
Revenue (ttm)
243.57M
Profit margin
9.54%
EPS (ttm)
0.46
Shares out
49.09M
P/E ratio
16.89
Forward P/E
11.71
YTD return
+30.59%
1-year return
+56.97%
Avg volume
363.90K
Previous close
7.77
52-week range
4.80 – 11.50
Beta
1.08
Price target
4.33 (-44.2%)
50-day average
2.94
200-day average
3.58
Enterprise value
124.64M
Price / sales
0.57

5D -0.41 (-5.01%)

7.7588.258.50MonTueWedThuFri7.77

Key statistics

Price / book
1.94
Revenue growth
43.50%
Free cash flow
32.70M
Total cash
96.72M
Total debt
86.37M
Return on equity
42.32%
Short % of float
6.74%

Fundamental scorecard

14 of 25 checks passed on PBYI’s reported financials

ValueGrowthProfitabilityHealthDividend

14of 25 checks passed

  • Value 3 of 5
  • Growth 2 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PBYI Revenue — quarterly 55.06M
PBYI Net income — quarterly 5.96M
PBYI EPS — quarterly 0.12

Earnings

PBYI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 20240.350.45+0.10+28.57%
Aug 1, 2024Jun 1, 2024-0.10-0.05+0.05+50.00%
May 2, 2024Mar 1, 2024-0.16-0.05+0.11+68.75%
Feb 29, 2024Dec 1, 20230.370.31-0.06-16.22%
Nov 2, 2023Sep 1, 20230.150.17+0.02+13.33%
Aug 3, 2023Jun 1, 20230.070.10+0.03+42.86%

Upgrades / downgrades

PBYI analyst upgrades and downgrades
DateFirmActionFromTo
Dec 23, 2024HC Wainwright & Co.reitBuyBuy
Nov 20, 2024HC Wainwright & Co.reitBuyBuy
Nov 8, 2024HC Wainwright & Co.reitBuyBuy
Aug 2, 2024HC Wainwright & Co.reitBuyBuy
Jul 26, 2024HC Wainwright & Co.reitBuyBuy
Jun 4, 2024HC Wainwright & Co.reitBuyBuy

About Puma Biotechnology, Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PBYI — it syncs with the Stock Master app.

Insider holders

PBYI insider holders
InsiderRelationLatest transactionDateShares held
AUERBACH ALAN HChief Executive OfficerSaleJul 16, 20247,063,520
DORVAL ALLISONDirectorStock Award(Grant)Jun 17, 202460,000
HUNT DOUGLAS MOfficerSaleJul 16, 2024133,227
LUDWIG JEFFREY JEROMEOfficerSaleJul 16, 2024118,388
MILLER MICHAEL PATRICKDirectorSaleAug 11, 202447,000
MOYES JAY MDirectorStock Award(Grant)Jun 17, 202448,322

Institution ownership

PBYI institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.80%3,827,22310.75MSep 29, 2024
Vanguard Group Inc7.41%3,636,19110.22MSep 29, 2024
Frazier Life Sciences Management, L.P. 6.24%3,062,5588.61MSep 29, 2024
Millennium Management Llc5.87%2,880,8888.10MSep 29, 2024
Acadian Asset Management. LLC4.01%1,968,9995.53MSep 29, 2024
Renaissance Technologies, LLC3.61%1,772,4134.98MSep 29, 2024

Fund ownership

PBYI fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.59%1,271,5643.57MSep 29, 2024
iShares Russell 2000 ETF2.20%1,080,7813.04MOct 30, 2024
Vanguard Explorer Fund, Inc.1.58%777,3902.18MJul 30, 2024
Avantis U.S. Small Cap Value ETF1.46%718,4542.02MSep 29, 2024
Vanguard Extended Market Index Fund1.19%585,8501.65MSep 29, 2024
Vanguard Strategic Equity Fund1.10%540,4341.52MSep 29, 2024